Clinical trials: Cancer: Solid Tumors
Solid Tumors
M3541 in Combination With Radiotherapy in Solid Tumors
This dose-escalation study evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in participants with…
- Trial name
- NCT03225105
- Testing
- M3541, Palliative Radiotherapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Refractory Solid Tumors, Melanoma
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
- Trial name
- ILLUMINATE-101 (NCT03052205)
- Testing
- IMO-2125
- Where
- 12 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers
RATIONALE: Giving healthy volunteers sulindac capsules or sulindac tablets may help doctors learn which form of the drug may be more effective in preventing cancer.
- Trial name
- NCT00343629
- Testing
- sulindac, pharmacological study
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Refractory Solid Tumors
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort.
- Trial name
- NCT00759928
- Testing
- Erlotinib, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Primary Objective To determine the safety and tolerability of Karonudib (TH1579) in escalating doses for the treatment of patients with advanced solid malignant tumours. Secondary Objective To define DLT and MTD.
- Trial name
- MASTIFF (NCT03036228)
- Testing
- Karonudib
- Where
- 3 sites in Sweden
- Volunteers
- 63 people
- Sponsor
- Thomas Helleday Foundation
Advanced Solid Tumor, Advanced Solid Malignancies
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in…
- Trial name
- NCT05315167
- Testing
- PRJ1-3024
- Where
- 5 sites in China
- Volunteers
- 267 people
- Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112892
- Testing
- selenium, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT02410512
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 610 people
- Sponsor
- Genentech, Inc.
Solid Tumor
Study of ICP-105 in Solid Tumors Patients
Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.
- Trial name
- NCT03642834
- Testing
- ICP-105
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Tumor, Solid
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
- Trial name
- NCT05637034
- Testing
- 68Ga-DOTA-F2 PET/CT and 18F-FDG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Solid Tumors, Non-small Cell Lung Cancer
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors including a specific kind of lung cancer (non-small cell lung cancer, NSCLC).
- Trial name
- NCT05858164
- Testing
- BAY2862789
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 45 people
- Sponsor
- Bayer
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory).
- Trial name
- NCT05038839
- Testing
- Cabozantinib, Pamiparib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Dysgeusia, Solid Tumor
A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment
This study is for people with a diagnosis of solid tumor cancer who are experiencing changes in taste perception due to cancer treatment.
- Trial name
- NCT07419581
- Testing
- MiraBurst
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on…
- Trial name
- NCT00064636
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Volunteers
- 46 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
- Trial name
- NCT05357911
- Testing
- AB-106, digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Breast Carcinoma, Colon Carcinoma
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
This clinical quality improvement study reviews and develops a clinical operations workflow to identify cancer patients who meet criteria for genetic counseling and testing.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT04902144
- Testing
- Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors
To study the normal physiological distribution of the probe 124I-EV in human body and its ability to detect overexpression of Nectin-4 in tumor lesions.
- Trial name
- NCT05322512
- Testing
- 18F-FDG
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.